Evaluation of renal protection by irbesartan and losartan in renal transplanted patients

Evaluation of renal protection by irbesartan and losartan in renal transplanted patients - I-LORD study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003359

Enrollment

140

Registered

2010-04-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal transplantation

Interventions

irbesartan 50 or 100mg, max 200mg losartan 25 or 50mg, max 100mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hypertension based on a guidline of JSH2009

Exclusion criteria

Exclusion criteria: renal failure (serum creatinine more than 2.5mg/dL) Child bearing women

Design outcomes

Primary

Measure	Time frame
alteration rate of eGFR serum cretinine levels	—

Secondary

Measure	Time frame
clinic blood pressure urinary MCP-1 albuminuria	—

Countries

Japan

Contacts

Public ContactHitoshi Yokoyama

Kanazawa Medical University, School of Medicine Division of Nephrology

h-yoko@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026